Intelligence

Home / Intelligence

Type
  • All
  • Blog
  • Briefs
  • Case Studies
  • Industry Publications
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Search

Unmet Need Associated With Available Therapeutic Options For Management Of Dyspareunia Related To Genitourinary Syndrome Of Menopause: A Systematic Literature Review

Genitourinary syndrome of menopause (GSM) is a chronic, progressive condition affecting up to 60% of post-menopausal women in the United States. Dyspareunia, or pain with sexual intercourse, has been recognized as one of GSM’s most bothersome symptoms. Despite high prevalence and availability of treatments, many women are not adequately managed, and unmet need remains. The objective of this systematic literature review was to characterize the unmet need. Authors S.S. Faubion, S.S. Karkare, K.R. Hennegan, N. Hadker, B.R. Robinson, M.Z. Lim-Watson…

Read Now

Predicting Hypoparathyroidism Diagnosis In Medicare Claims — Exploring The Utility Of Sequence Analysis

Claims-based prediction models commonly use dichotomous indicator variables (e.g., presence/absence of disease) or count variables (e.g., frequency of claims) as predictors. The research objective was to compare the predictive ability of this standard model with other models that account for the sequence of events. The models were applied in the context of predicting hypoparathyroidism diagnosis among Medicare beneficiaries. Authors Site Li, Bingqing Yu, Xinyi Wang, Guangyan Yu, Diptanshu Singh, Gavin Miyasato, Masanao Yajima Journal ISPOR Meeting, May 2019 View publication…

Read Now

PharmaVOICE: TGaS® Advisors Patient-Centricity Study

“A key improvement that we have seen in the industry is centralizing resources — both headcount and budget — outside of the brand team. This allows companies to focus on key initiatives, such as patient health literacy, patient co-creation activities, and even call center dialogue that can help break down the barriers of a complex conversations into a human dialogue,” says Sue Lipinski, executive director, omnichannel marketing, TGaS® Advisors. A January 2019 TGaS Advisors study polled pharmaceutical marketers about their…

Read Now

LTEN: What Can L&D Leaders Learn from Value-Based Care?

When I was a young pharmaceutical hospital representative, I had at least five products to promote to five different hospitals and to at least 12 different specialties. I vividly remember being on a conference call (on a grimy pay phone) where I was told that beginning that moment, one of our products would change from 20 percent to 90 percent of our territory’s performance weighting. And I turned on a dime. Was I or anyone else considering the effects my lack…

Read Now

Assessing Healthcare Resource Utilization Across Segments of Obesity — A Retrospective Claims Study

Obesity is a disease that is caused and influenced by genes and the environment. Whether different etiologies or presentations of obesity result in homogeneous disease burden and/or cost is not well characterized. The objective is to determine whether there are distinct segments within the pool of patients who are obese that are differentiated by clinical characteristics, and quantify their healthcare resource utilization (direct healthcare costs [HCC]), using U.S. claims data. Authors Marissa Suh, Monica Fay, Amy McCagg, Ida Moeller, Scott…

Read Now

PM360: Key Questions About Social Media in 2019

Read in PM360. Sue Lipinski, TGaS® Advisors, a division of Trinity At an individual brand level, it’s highly unlikely that social media platform activity will decrease based upon the social media scandals from 2018. Most of the marketing efforts that TGaS benchmarks are showing that brands leverage these platforms intelligently and with great consideration. Now, if their key driver analysis (KDA) or ROI analysis indicates little to no value from social media, then you will see a decrease. However, at…

Read Now

How to Approach Asset Valuation in Pharma & Biotech:

Pharma and biotech companies are innovation drivers at the frontlines of research and development. To fund and support this promising science, there is a great need for partnerships and mergers and acquisitions (M&A) to drive the growth/pipeline of the industry. For these collaborative relationships to occur, understanding the value of a company’s underlying assets is of the utmost importance. Since Trinity’s founding, multiple pharma and biotech clients have relied on its expertise in forecast and valuing assets. These engagements have…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.